These results imply that despite low BCMA expression on primary CLL cells, these cells can be lysed by teclistamab upon coculture with autologous T cells, but leads to lower cytotoxicity compared with multiple myeloma. This evidence concerns the gene TNFRSF17 and plasma cell myeloma.